Arrowhead Pharmaceuticals/$ARWR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
- Ticker
- $ARWR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 711
- Headquarters
- Pasadena, United States
- Website
- arrowheadpharma.com
ARWR Metrics
BasicAdvanced
$8.5B
-
-$2.28
1.29
-
Price and volume
Market cap
$8.5B
Beta
1.29
52-week high
$95.49
52-week low
$37.06
Average daily volume
1.9M
Financial strength
Current ratio
5.899
Quick ratio
5.706
Long term debt to equity
2.856
Total debt to equity
2.96
Interest coverage (TTM)
-2.45%
Profitability
EBITDA (TTM)
-200.635
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-47.79%
Operating margin (TTM)
-33.82%
Effective tax rate (TTM)
-7.95%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-8.10%
Return on equity (TTM)
-55.21%
Valuation
Price to revenue (TTM)
12.691
Price to book
18.34
Price to tangible book (TTM)
18.56
Price to free cash flow (TTM)
-113.124
Free cash flow yield (TTM)
-0.88%
Free cash flow per share (TTM)
-0.535
Growth
Revenue change (TTM)
16.85%
Earnings per share change (TTM)
100.62%
3-year revenue growth (CAGR)
37.74%
10-year revenue growth (CAGR)
128.73%
3-year earnings per share growth (CAGR)
10.23%
10-year earnings per share growth (CAGR)
4.93%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
Analyst projections of the future price of Arrowhead Pharmaceuticals stock.
Bulls say / Bears say
Plozasiran delivered about 80% median triglyceride reductions in both Phase 3 SHASTA studies, and the results also showed fewer acute pancreatitis events. This gives Arrowhead strong clinical evidence for a broader use beyond its current rare-disease market. (Business Wire)
The FDA has accepted plozasiran into its STAR pilot, which allows a six-month priority review and may enable an even earlier decision. Arrowhead says it remains on schedule to file for severe hypertriglyceridaemia by the end of 2026. (Arrowhead Pharmaceuticals)
REDEMPLO’s US launch is gaining traction: prescriptions roughly doubled in the latest reported quarter, with more than 400 practitioners prescribing it. The medicine also has approvals across the US, EU, China, Australia and Canada, expanding its commercial reach. (Arrowhead Pharmaceuticals, Nasdaq)
Arrowhead remains loss-making as it scales up: it reported a $194 million quarterly net loss, while REDEMPLO sales were only about $2.4 million. Much of reported revenue still came from collaborations rather than product sales. (Nasdaq, Earningscalls.dev)
Arrowhead faces an established competitor in severe hypertriglyceridaemia, and management acknowledged that the rival is ahead. Even with promising trial results, a later launch could make it harder to win early prescribers and market share. (Earningscalls.dev)
The positive dual-target RNAi results are still early: ARO-DIMER-PA is in Phase 1/2a, and the reported study is continuing to assess safety and tolerability with repeat dosing. Its lipid changes therefore do not yet establish durable benefit or success in later-stage trials. (Arrowhead Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARWR News
AllArticlesVideos
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Business Wire3 days ago
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
MarketBeat2 weeks ago
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Business Wire2 weeks ago
Funds containing ARWR
AllUSDEURGBP
Fund name | Fund size | $ARWR weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.82% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.82% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.82% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.55% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.55% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.